Celebrities like Mandy Moore, Brooke Shields and Marisa Tomei attended a Hollywood charity event last March to help launch the Latisse Wishes campaign, a campaign to support the Make-A-Wish foundation and generate interest in the new eyelash enhancement drug. The Make-A-Wish foundation is known for granting the wishes of suffering children.

Latisse, Allergan’s new eyelash enhancer and latest offering, is the first drug to be approved by the FDA for the treatment of hypotrichosis, a condition characterized by inadequate eyelashes. The Latisse Wishes campaign was launched by Allergan with a $500,000 initial contribution to Make-A-Wish.

Hollywood beauty expert and participant, Anastasia Soare, enthusiastically expressed her support, saying “I constantly work to help make women’s beauty wishes come true, and now we can help children’s wishes come true through the LATISSE™ Wishes campaign.”

It’s not a mere coincidence that Make-A-Wish was chosen as a beneficiary for Allergan’s campaign; the superstitious tradition of blowing on an eyelash to make a wish come true, provides a clever marketing strategy, backed by philanthropy.

The campaign is encouraging consumers to help double the donation amount by visiting www.Latisse.com and registering their support. From now until the end of the year, Allergan will donate 5 dollars for each new registration, up to one million dollars.

Latisse is now available in Chicago and Munster, Indiana; contact us for more information.

The hot new eyelash enhancement drug Latisse is now available in Frankfort and Munster!

Last month, the FDA gave Botox/Juvederm manufacturer Allergan its stamp of approval for Latisse.  Now, the hot new drug is becoming available through certain providers.

What is Latisse? If you haven’t heard yet, it is a special eyelash treatment that is applied to the base of the lashes.  Latisse keeps hairs in their growth phase, producing darker, fuller and longer eyelashes. The aesthetic results of Latisse are desirable, but not permanent; patients must keep using it in order to maintain its effects.

Like many new drugs in recent years, the effects of Latisse were discovered inadvertently. During clinical trials for a glaucoma eye drop called Lumigan, researchers noticed an unintended side effect; patients exhibited longer, fuller lashes.  To make it brief: further research was conducted, the active ingredient (bimatoprost) was reduced, and now many patients can have the long, desirable eyelashes they’ve always wanted.

For more details about special introductory pricing, contact us at 815-806-9400.